The insidious impact of under-diagnosed proximal weakness induced by statins

References

• Fabiana R, Santos RD. The role of statins in current guidelines. Curr Atheroscler Rep. 2020;22:50.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559.
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316:2008–2024.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact of statin therapy – European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39:e38–81.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(Suppl):S58–S71.
   PubMedGoogle Scholar
• Abdullah K, Rohatgi A. Statins: practical considerations – a review. Eur Cardiol Rev. 2014;9: 71–75.
   PubMedGoogle Scholar
• Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–580.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Brinton EA, Ito MK, et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–215.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414.
   PubMed Web of Science ®Google Scholar
• Lowenstern A, Navar AM, Li S, et al. Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels (a survey of US practice in the PALM registry). Am J Cardiol. 2019;123:1011–1018.
   PubMed Web of Science ®Google Scholar
• Bradley CK, Wang TY, Li S, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8:e011765.
   PubMed Web of Science ®Google Scholar
• Nelson AJ, Puri R, Nissen SE. Statins in a distorted mirror of media. Curr Atheroscler Rep. 2020;22:37.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al.; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580–1590.
   PubMed Web of Science ®Google Scholar
• Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Eng J Med. 2020 Nov 15;383(22):2182–2184.
   Web of Science ®Google Scholar
• Dobkin BH. Fatigue versus activity-dependent fatigability in patients with central or peripheral motor impairments. Neurorehabil Neural Repair. 2008;22:105–110.
   PubMed Web of Science ®Google Scholar
• Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005;19(3):259–263.
   PubMed Web of Science ®Google Scholar
• Gras-Champel V, Batteux B, Masmoudi K, et al. Statin induced myasthenia: a disproportionality analysis of the WHO’s VigiBase pharmacovigilance database. Muscle Nerve. 2019;60:382–386.
   PubMed Web of Science ®Google Scholar
• Oh S, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38:1101–1107.
   PubMed Web of Science ®Google Scholar
• Janssen L, Allard NAE, Saris CGJ, et al. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100:633–672.
   PubMed Web of Science ®Google Scholar
• Muntean DM, Thompson PD, Catapano AL, et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today. 2017;22:85–96.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6–15.
   PubMed Web of Science ®Google Scholar
• Parker BA, Capizzi JA, Grimaldi A, et al. The effect of statins on skeletal muscle function. Circulation. 2013;127:96–103.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Miller K, Bayliss M, et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and interrater reliability. Cardiovasc Drugs Ther. 2017;31:179–186.
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–585.
   PubMed Web of Science ®Google Scholar
• Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Clevel Clin J Med. 2011;78:393–403.
   PubMedGoogle Scholar
• Scott D, Blizzard L, Fell J, et al. Statin therapy, muscle function and falls risk in community-dwelling older adults. Q J Med. 2009;102:625–633.
   Google Scholar
• Panza GA, Taylor BA, Dada MR, et al. Changes in muscle strength in individuals with statin-induced myopathy. J Clin Lipidol. 2015;9:351–356.
   PubMed Web of Science ®Google Scholar
• Taylor BA, Lorson L, White M, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329–335.
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statin on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322:1780–1788.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. For the CLEAR Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–1032.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415.
   PubMed Web of Science ®Google Scholar
• Burke MJ. “It’s all in your head” – medicine’s silent epidemic. JAMA Neurol. 2019;76:1417–1418.
   PubMed Web of Science ®Google Scholar